Fabrication and Modelling of a Reservoir-Based Drug Delivery System for Customizable Release.
computational modelling
diffusion-controlled
drug delivery system
drug reservoir
glioblastoma
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
02 Apr 2022
02 Apr 2022
Historique:
received:
08
03
2022
revised:
29
03
2022
accepted:
29
03
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
Localized therapy approaches have emerged as an alternative drug administration route to overcome the limitations of systemic therapies, such as the crossing of the blood-brain barrier in the case of brain tumor treatment. For this, implantable drug delivery systems (DDS) have been developed and extensively researched. However, to achieve an effective localized treatment, the release kinetics of DDS needs to be controlled in a defined manner, so that the concentration at the tumor site is within the therapeutic window. Thus, a DDS, with patient-specific release kinetics, is crucial for the improvement of therapy. Here, we present a computationally supported reservoir-based DDS (rDDS) development towards patient-specific release kinetics. The rDDS consists of a reservoir surrounded by a polydimethylsiloxane (PDMS) microchannel membrane. By tailoring the rDDS, in terms of membrane porosity, geometry, and drug concentration, the release profiles can be precisely adapted, with respect to the maximum concentration, release rate, and release time. The release is investigated using a model dye for varying parameters, leading to different distinct release profiles, with a maximum release of up to 60 days. Finally, a computational simulation, considering exemplary in vivo conditions (e.g., exchange of cerebrospinal fluid), is used to study the resulting drug release profiles, demonstrating the customizability of the system. The establishment of a computationally supported workflow, for development towards a patient-specific rDDS, in combination with the transfer to suitable drugs, could significantly improve the efficacy of localized therapy approaches.
Identifiants
pubmed: 35456611
pii: pharmaceutics14040777
doi: 10.3390/pharmaceutics14040777
pmc: PMC9025308
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : GRK2154
Références
Adv Mater. 2010 Nov 24;22(44):4925-43
pubmed: 20818618
Pharmaceutics. 2022 Jan 05;14(1):
pubmed: 35057020
ACS Appl Mater Interfaces. 2020 Apr 29;12(17):19345-19356
pubmed: 32252517
Nat Commun. 2019 Nov 15;10(1):5205
pubmed: 31729383
Neuro Oncol. 2015 Mar;17 Suppl 2:ii9-ii23
pubmed: 25746091
Pharmaceutics. 2020 Oct 06;12(10):
pubmed: 33036139
J Control Release. 2014 Sep 28;190:75-81
pubmed: 24998939
J Control Release. 2016 Dec 10;243:29-42
pubmed: 27693428
Opt Express. 2016 Oct 31;24(22):25129-25147
pubmed: 27828452
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022 May;14(3):e1772
pubmed: 34964277
Polymers (Basel). 2018 Dec 12;10(12):
pubmed: 30961303
Nat Rev Drug Discov. 2021 Feb;20(2):101-124
pubmed: 33277608
Cancer. 2004 Jan 15;100(2):405-10
pubmed: 14716778
Int J Nanomedicine. 2021 Jul 06;16:4597-4614
pubmed: 34267515
ACS Chem Neurosci. 2020 Oct 7;11(19):2962-2977
pubmed: 32945654
Drug Deliv. 2010 Aug;17(6):365-75
pubmed: 20429844
Adv Mater. 2022 Jan;34(1):e2106606
pubmed: 34618380
ACS Biomater Sci Eng. 2020 Jun 8;6(6):3388-3397
pubmed: 33463157
ACS Nano. 2014 Oct 28;8(10):10655-64
pubmed: 25259648
Bone. 2010 Dec;47(6):1076-9
pubmed: 20817052
Neuro Oncol. 2003 Apr;5(2):79-88
pubmed: 12672279
J Control Release. 2019 Sep 10;309:72-81
pubmed: 31306678
Oncotarget. 2015 May 10;6(13):10950-63
pubmed: 25860932
Expert Rev Anticancer Ther. 2008 Mar;8(3):343-59
pubmed: 18366283
Sci Rep. 2017 Mar 06;7:43271
pubmed: 28262735
J Control Release. 2012 Jul 20;161(2):351-62
pubmed: 22019555
Adv Drug Deliv Rev. 2021 Oct;177:113951
pubmed: 34461201
J Neurosurg. 2009 Mar;110(3):583-8
pubmed: 19046047
J Neurosurg. 1991 Mar;74(3):441-6
pubmed: 1993909
Invest New Drugs. 2004 Jan;22(1):27-37
pubmed: 14707492
J Phys Chem B. 2019 Oct 17;123(41):8838-8847
pubmed: 31545046
Ultramicroscopy. 2015 Oct;157:35-47
pubmed: 26057688
Adv Mater. 2019 Mar;31(9):e1800662
pubmed: 30039878
Ann Biomed Eng. 2011 Jan;39(1):484-96
pubmed: 20737291
ACS Appl Mater Interfaces. 2015 Jul 8;7(26):14303-16
pubmed: 26050666
Biomaterials. 2018 Sep;178:373-382
pubmed: 29779862
Drug Deliv. 2016;23(3):999-1016
pubmed: 25026415
Int J Nanomedicine. 2020 Apr 17;15:2563-2582
pubmed: 32368041
Adv Healthc Mater. 2018 Mar;7(6):e1701024
pubmed: 29210522
Nat Nanotechnol. 2021 Jul;16(7):820-829
pubmed: 33795849
Sci Rep. 2018 Jun 20;8(1):9377
pubmed: 29925966
Front Med Technol. 2021 Nov 22;3:791596
pubmed: 35047971
Cancers (Basel). 2021 Mar 09;13(5):
pubmed: 33803133
Biomedicines. 2021 Mar 22;9(3):
pubmed: 33810154
Adv Mater. 2018 May 7;:e1705328
pubmed: 29736981
Biomed Pharmacother. 2021 Nov;143:112144
pubmed: 34509823
Adv Drug Deliv Rev. 2015 Aug 30;91:23-37
pubmed: 25895620
Sci Rep. 2019 Nov 29;9(1):17936
pubmed: 31784666
Nat Protoc. 2014 Feb;9(2):294-304
pubmed: 24407356
Int J Mol Sci. 2021 Dec 06;22(23):
pubmed: 34884965